Bekhti A, Schaaps J P, Capron M, Dessaint J P, Santoro F, Capron A
Br Med J. 1977 Oct 22;2(6094):1047-51. doi: 10.1136/bmj.2.6094.1047.
Mebendazole was given to four patients with hepatic hydatid disease. In three patients hydatidosis had remained after surgery, and in the fourth it could not be treated surgically. Mebendazole was given orally in maximum doses of 400-600 mg three times a day during courses lasting 21 to 30 days. Ultrasonic echotomography showed a complete regression of the intrahepatic cysts after four to 13 months in all four cases. In three patients the course of treatment had to be repeated. Mebendazole also induced clinical improvement and a progressive lowering of the concentration of specific IgE of Echinococcus granulosus. During treatment circulating blood levels of specific immune complexes of antigen 5 were increased. These observations indicate that mebendazole has a lethal effect on E granulosus cysts in primary hydatid disease in man and that the efficacy of chemotherapy can be assessed with ultrasonography and by measuring changes in the concentration of specific IgE of E granulosus and circulating immune complexes.
给四名肝包虫病患者服用了甲苯咪唑。三名患者术后仍有包虫病,第四名患者无法进行手术治疗。甲苯咪唑以最大剂量400 - 600毫克口服,每日三次,疗程持续21至30天。超声断层扫描显示,所有四例患者在4至13个月后肝内囊肿完全消退。三名患者的治疗过程需要重复。甲苯咪唑还使临床症状改善,细粒棘球绦虫特异性IgE浓度逐渐降低。治疗期间,抗原5特异性免疫复合物的循环血液水平升高。这些观察结果表明,甲苯咪唑对人类原发性包虫病中的细粒棘球绦虫囊肿具有致死作用,化疗效果可通过超声检查以及测量细粒棘球绦虫特异性IgE浓度和循环免疫复合物的变化来评估。